|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM63A |
Gene summary for TMEM63A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM63A | Gene ID | 9725 |
| Gene name | transmembrane protein 63A | |
| Gene Alias | HLD19 | |
| Cytomap | 1q42.12 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024R3T3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9725 | TMEM63A | A002-C-114 | Human | Colorectum | FAP | 9.19e-17 | -7.66e-02 | -0.1561 |
| 9725 | TMEM63A | A015-C-104 | Human | Colorectum | FAP | 2.68e-23 | -9.11e-02 | -0.1899 |
| 9725 | TMEM63A | A001-C-014 | Human | Colorectum | FAP | 2.46e-08 | -1.11e-01 | 0.0135 |
| 9725 | TMEM63A | A002-C-016 | Human | Colorectum | FAP | 1.75e-18 | -2.75e-01 | 0.0521 |
| 9725 | TMEM63A | A015-C-002 | Human | Colorectum | FAP | 1.92e-10 | -2.80e-01 | -0.0763 |
| 9725 | TMEM63A | A001-C-203 | Human | Colorectum | FAP | 4.84e-07 | 7.28e-02 | -0.0481 |
| 9725 | TMEM63A | A002-C-116 | Human | Colorectum | FAP | 2.32e-24 | -2.30e-01 | -0.0452 |
| 9725 | TMEM63A | A014-C-008 | Human | Colorectum | FAP | 7.05e-13 | -1.57e-01 | -0.191 |
| 9725 | TMEM63A | A018-E-020 | Human | Colorectum | FAP | 9.32e-17 | -1.85e-01 | -0.2034 |
| 9725 | TMEM63A | F034 | Human | Colorectum | FAP | 1.54e-15 | -9.67e-02 | -0.0665 |
| 9725 | TMEM63A | F072B | Human | Colorectum | FAP | 2.50e-05 | -2.97e-03 | 0.257 |
| 9725 | TMEM63A | CRC-3-11773 | Human | Colorectum | CRC | 2.42e-04 | 1.68e-01 | 0.2564 |
| 9725 | TMEM63A | LZE7T | Human | Esophagus | ESCC | 3.66e-02 | 2.01e-01 | 0.0667 |
| 9725 | TMEM63A | LZE20T | Human | Esophagus | ESCC | 5.20e-03 | 2.52e-02 | 0.0662 |
| 9725 | TMEM63A | LZE24T | Human | Esophagus | ESCC | 1.40e-06 | 4.69e-02 | 0.0596 |
| 9725 | TMEM63A | P1T-E | Human | Esophagus | ESCC | 5.19e-06 | 2.14e-01 | 0.0875 |
| 9725 | TMEM63A | P2T-E | Human | Esophagus | ESCC | 7.25e-30 | 2.86e-01 | 0.1177 |
| 9725 | TMEM63A | P5T-E | Human | Esophagus | ESCC | 1.20e-06 | -4.36e-02 | 0.1327 |
| 9725 | TMEM63A | P8T-E | Human | Esophagus | ESCC | 2.30e-12 | 1.60e-01 | 0.0889 |
| 9725 | TMEM63A | P9T-E | Human | Esophagus | ESCC | 1.13e-04 | 5.22e-02 | 0.1131 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM63A | SNV | Missense_Mutation | novel | c.1096G>T | p.Asp366Tyr | p.D366Y | O94886 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM63A | SNV | Missense_Mutation | rs376648031 | c.2086G>A | p.Ala696Thr | p.A696T | O94886 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM63A | SNV | Missense_Mutation | rs760750326 | c.1751N>A | p.Arg584His | p.R584H | O94886 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
| TMEM63A | insertion | Nonsense_Mutation | novel | c.975_976insTCTGAGAGAATAATTGTTCCCTCTGAGCTCTTGGGGACCTAAG | p.Arg326SerfsTer14 | p.R326Sfs*14 | O94886 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| TMEM63A | insertion | Frame_Shift_Ins | novel | c.790_791insGCAA | p.Tyr264CysfsTer18 | p.Y264Cfs*18 | O94886 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
| TMEM63A | insertion | In_Frame_Ins | novel | c.789_790insAAGTGTCAGAGCCTTCAG | p.Cys263_Tyr264insLysCysGlnSerLeuGln | p.C263_Y264insKCQSLQ | O94886 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
| TMEM63A | deletion | Frame_Shift_Del | c.505delG | p.Asp169ThrfsTer15 | p.D169Tfs*15 | O94886 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| TMEM63A | SNV | Missense_Mutation | novel | c.1523T>C | p.Ile508Thr | p.I508T | O94886 | protein_coding | tolerated(0.47) | benign(0.124) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TMEM63A | SNV | Missense_Mutation | novel | c.2362C>A | p.Pro788Thr | p.P788T | O94886 | protein_coding | tolerated(0.53) | benign(0.025) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM63A | SNV | Missense_Mutation | rs753026260 | c.1474C>T | p.His492Tyr | p.H492Y | O94886 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |